PLSE - Pulse Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Pulse Biosciences, Inc.

3957 Point Eden Way
Hayward, CA 94545
United States
650-697-3939
http://www.pulsebiosciences.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees33

Key Executives

NameTitlePayExercisedYear Born
Mr. Darrin R. UeckerPres, CEO & Director416.82kN/A1966
Mr. Brian B. DowCFO, Sr. VP of Fin. & Admin., Treasurer and Sec.309.25kN/A1969
Dr. Richard Nuccitelli Ph.D.Chief Science OfficerN/AN/AN/A
Dr. Holly Hartman Ph.D., J.D.VP of Bus. Devel. & Corp. StrategyN/AN/AN/A
Mr. David DanitzVP of EngineeringN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

Corporate Governance

Pulse Biosciences, Inc.’s ISS Governance QualityScore as of December 1, 2018 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.